Skip to content

Insiders are buying these two stocks in 2023

Insiders are buying these two stocks in 2023

When company insiders — management, officers or any beneficial owners with more than 10% of a company’s shares, as defined by the SEC — buy shares of their own company it’s a bullish sign. That’s because they believe the stock price will rise in the future.

Luckily, insiders must file SEC forms every time they buy or sell shares, which is how we can track who is buying and who is selling.

Since insider purchases are considered a bullish sign, Finbold analyzed insider purchases in 2023 and selected the two companies where most insiders bought shares this year.

B. Riley Financial

B. Riley Financial (NASDAQ: RILY) is a financial services platform that provides tailored financial solutions in areas such as investment banking, real estate, retail, venture capital, wealth management, auction and liquidation, bankruptcy, restructuring and more.

In 2023, Riley Financial had 19 insiders purchase a total of 433,841 shares at an average price of $40,65. That’s $17.6 million worth of shares, making it the largest insider purchase this year.

Recent RILY insider purchases. Source: Finviz

Morningstar’s quantitative equity report has a fair value estimate of $79.86 per share for RILY, while the company trades at $53.96 at the moment. That’s a 47% difference if Morningstar’s fair value is reached in the future.

Morningstar quantitative equity report. Source: Interactive Brokers Fundamentals Explorer

Better Therapeutics

Better Therapeutics (NASDAQ: BTTX) is a prescription digital therapeutics company engaged in developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases.

This is the second most-purchased stock by insiders in 2023. So far, 10 insiders bought 8,236,319 shares at an average price of $1.25. That’s $8 million worth of shares scooped up by company insiders.

Recent BTTX insider purchases. Source: Finviz

BTTX shares currently trade at $0.71, while Morningstar’s quantitative equity report has given a fair value estimate of $1.22, around what the insiders paid on average.

Morningstar quantitative equity report. Source: Interactive Brokers Fundamentals Explorer


BTTX has had a rough year, returning -35% year to date, while RILY outperformed the S&P 500’s 17% return with a 57% gain during the same period.

Buy stocks now with Interactive Brokers – the most advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Services

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.